ENDRA Life Sciences (NDRA) Tops Q4 EPS by 1c

ENDRA Life Sciences (NASDAQ: NDRA) reported Q4 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08).

Cash and cash equivalents were $9.5 million as of December 31, 2021.

For earnings history and earnings-related data on ENDRA Life Sciences (NDRA) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• XP Inc. (XP) Tops Q2 EPS by 8c